2020年

1. Enhanced immune reaction resulting from co-vaccination of WT1 helper peptide assessed on PET-CT.

   Jun Nakata, Kayako Isohashi, Soyoko Morimoto, Ryota Itou, Takashi Kamiya, Ai Matsuura, Hiroko Nakajima, Fumihiro Fujiki, Sumiyuki Nishida, Yoshiko Hasii, Kana Hasegawa, Shinichi Nakatsuka, Naoki Hosen, Akihiro Tsuboi, Yoshihiro Oka, Atsushi Kumanogoh, Masaru Shibano, Satoru Munakata, Yusuke Oji, Jun Hatazawa, Haruo Sugiyama

   Medicine 99(39) e22417 2020年9月25日FullTxt

2. Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides.

   Fumihiro Fujiki, Akihiro Tsuboi, Soyoko Morimoto, Naoya Hashimoto, Miki Inatome, Hiroko Nakajima, Jun Nakata, Sumiyuki Nishida, Kana Hasegawa, Naoki Hosen, Yoshihiro Oka, Yusuke Oji, Shinji Sogo, Haruo Sugiyama

   Cancer immunology, immunotherapy : CII 2020年7月22日FullTxt

3. Reader-free ELISPOT assay for immuno-monitoring in peptide-based cancer vaccine immunotherapy.

   Sae Hayashi, Rin Imanishi, Mayuko Adachi, Sayaka Ikejima, Jun Nakata, Soyoko Morimoto, Fumihiro Fujiki, Sumiyuki Nishida, Akihiro Tsuboi, Naoki Hosen, Hiroko Nakajima, Kana Hasegawa, Yoshihiro Oka, Haruo Sugiyama, Yusuke Oji

   Biomedical reports 12(5) 244 - 250 2020年5月FullTxt

2019年

1. What should we tackle next in acute myeloid leukemia? Wilms tumor gene 1 vaccine therapy would be a promising and versatile strategy for acute myeloid leukemia.

   Nakata J, Oji Y, Oka Y, Sugiyama H

   Expert review of hematology　1-3　2019年3月FullTxt

2018年

1. Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides.

   Nakata J, Nakajima H, Hayashibara H, Imafuku K, Morimoto S, Fujiki F, Motooka D, Okuzaki D, Hasegawa K, Hosen N, Tsuboi A, Oka Y, Kumanogoh A, Oji Y, Sugiyama H

   Oncotarget　9(89) 36029-36038　2018年11月FullTxt

2. A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.

   Tsuboi A, Hashimoto N, Fujiki F, Morimoto S, Kagawa N, Nakajima H, Hosen N, Nishida S, Nakata J, Morita S, Sakamoto J, Oji Y, Oka Y, Sugiyama H

   Cancer immunology, immunotherapy : CII　2018年11月FullTxt

3. Establishment of a novel platform cell line for efficient and precise evaluation of T cell receptor functional avidity.

   Morimoto S, Fujiki F, Kondo K, Nakajima H, Kobayashi Y, Inatome M, Aoyama N, Nishida Y, Tsuboi A, Oka Y, Nishida S, Nakata J, Hosen N, Oji Y, Sugiyama H

   Oncotarget　9(75) 34132-34141　2018年9月FullTxt

4. Prognostic significance of Wilms' tumor 1 expression in patients with pancreatic ductal adenocarcinoma.

   Kanai T, Ito Z, Oji Y, Suka M, Nishida S, Takakura K, Kajihara M, Saruta M, Fujioka S, Misawa T, Akiba T, Yanagisawa H, Shimodaira S, Okamoto M, Sugiyama H, Koido S

   Oncology letters　16(2) 2682-2692　2018年8月FullTxt

5. Wilms tumour 1 peptide vaccine as a cure-oriented post-chemotherapy strategy for patients with acute myeloid leukaemia at high risk of relapse.

   Nakata J, Nakae Y, Kawakami M, Morimoto S, Motooka D, Hosen N, Fujiki F, Nakajima H, Hasegawa K, Nishida S, Tsuboi A, Oji Y, Oka Y, Kumanogoh A, Sugiyama H

   British journal of haematology　182(2) 287-290　2018年7月FullTxt

6. WT1 peptide-based immunotherapy for advanced thymic epithelial malignancies.

   Oji Y, Inoue M, Takeda Y, Hosen N, Shintani Y, Kawakami M, Harada T, Murakami Y, Iwai M, Fukuda M, Nishida S, Nakata J, Nakae Y, Takashima S, Shirakata T, Nakajima H, Hasegawa K, Kida H, Kijima T, Morimoto S, Fujiki F, Tsuboi A, Morii E, Morita S, Sakamoto J, Kumanogoh A, Oka Y, Okumura M, Sugiyama H

   International journal of cancer　142(11) 2375-2382　2018年6月FullTxt

2017年

1. The activated conformation of integrin β7 is a novel multiple myeloma-specific target for CAR T cell therapy.

   Hosen N, Matsunaga Y, Hasegawa K, Matsuno H, Nakamura Y, Makita M, Watanabe K, Yoshida M, Satoh K, Morimoto S, Fujiki F, Nakajima H, Nakata J, Nishida S, Tsuboi A, Oka Y, Manabe M, Ichihara H, Aoyama Y, Mugitani A, Nakao T, Hino M, Uchibori R, Ozawa K, Baba Y, Terakura S, Wada N, Morii E, Nishimura J, Takeda K, Oji Y, Sugiyama H, Takagi J, Kumanogoh A

   Nature medicine　23(12) 1436-1443　2017年12月FullTxt

2. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.

   Anguille S, Van de Velde AL, Smits EL, Van Tendeloo VF, Juliusson G, Cools N, Nijs G, Stein B, Lion E, Van Driessche A, Vandenbosch I, Verlinden A, Gadisseur AP, Schroyens WA, Muylle L, Vermeulen K, Maes MB, Deiteren K, Malfait R, Gostick E, Lammens M, Couttenye MM, Jorens P, Goossens H, Price DA, Ladell K, Oka Y, Fujiki F, Oji Y, Sugiyama H, Berneman ZN

   Blood　130(15) 1713-1721　2017年10月FullTxt

3. Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.

   Oka Y, Tsuboi A, Nakata J, Nishida S, Hosen N, Kumanogoh A, Oji Y, Sugiyama H

   Oncology research and treatment　40(11) 682-690　2017年FullTxt

2016年

1. A Zbtb7a proto-oncogene as a novel target for miR-125a.

   Hojo N, Tatsumi N, Moriguchi N, Matsumura A, Morimoto S, Nakata J, Fujiki F, Nishida S, Nakajima H, Tsuboi A, Oka Y, Hosen N, Hayashi S, Sugiyama H, Oji Y

   Molecular carcinogenesis　55(12) 2001-2009　2016年12月FullTxt

2. Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine.

   Takashima S, Oka Y, Fujiki F, Morimoto S, Nakajima H, Nakae Y, Nakata J, Nishida S, Hosen N, Tatsumi N, Mizuguchi K, Hashimoto N, Oji Y, Tsuboi A, Kumanogoh A, Sugiyama H

   Future science OA　2(4) FSO96　2016年12月FullTxt

3. Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide.

   Oji Y, Hashimoto N, Tsuboi A, Murakami Y, Iwai M, Kagawa N, Chiba Y, Izumoto S, Elisseeva O, Ichinohasama R, Sakamoto J, Morita S, Nakajima H, Takashima S, Nakae Y, Nakata J, Kawakami M, Nishida S, Hosen N, Fujiki F, Morimoto S, Adachi M, Iwamoto M, Oka Y, Yoshimine T, Sugiyama H

   International journal of cancer　139(6) 1391-1401　2016年9月FullTxt

4. Induction of eEF2-specific antitumor CTL responses in vivo by vaccination with eEF2-derived 9mer-peptides.

   Nakajima H, Murakami Y, Morii E, Akao T, Tatsumi N, Odajima S, Fukuda M, Machitani T, Iwai M, Kawata S, Hojo N, Oka Y, Sugiyama H, Oji Y

   Oncology reports　35(4) 1959-1966　2016年4月FullTxt

5. An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells.

   Kondo K, Fujiki F, Nakajima H, Yatsukawa E, Morimoto S, Tatsumi N, Nishida S, Nakata J, Oka Y, Tsuboi A, Hosen N, Oji Y, Sugiyama H

   Journal of immunotherapy (Hagerstown, Md. : 1997)　39(3) 127-139　2016年4月FullTxt

6. Feasibility of Cancer Immunotherapy with WT1 Peptide Vaccination for Solid and Hematological Malignancies in Children.

   Sawada A, Inoue M, Kondo O, Yamada-Nakata K, Ishihara T, Kuwae Y, Nishikawa M, Ammori Y, Tsuboi A, Oji Y, Koyama-Sato M, Oka Y, Yasui M, Sugiyama H, Kawa K

   Pediatric blood & cancer　63(2) 234-241　2016年2月FullTxt

7. Glycosylation Status of CD43 Protein Is Associated with Resistance of Leukemia Cells to CTL-Mediated Cytolysis.

   Hasegawa K, Tanaka S, Fujiki F, Morimoto S, Nakano K, Kinoshita H, Okumura A, Fujioka Y, Urakawa R, Nakajima H, Tatsumi N, Nakata J, Takashima S, Nishida S, Tsuboi A, Oka Y, Oji Y, Miyoshi E, Hirata T, Kumanogoh A, Sugiyama H, Hosen N

   PloS one　11(3) e0152326　2016年FullTxt

8. Wilms tumor 1 peptide vaccination after hematopoietic stem cell transplant in leukemia patients.

   Hosen N, Maeda T, Hashii Y, Tsuboi A, Nishida S, Nakata J, Oji Y, Oka Y, Sugiyama H

   Stem cell investigation　3 90　2016年FullTxt

2015年

1. Wilms' tumor gene WT1 promotes homologous recombination-mediated DNA damage repair.

   Oji Y, Tatsumi N, Kobayashi J, Fukuda M, Ueda T, Nakano E, Saito C, Shibata S, Sumikawa M, Fukushima H, Saito A, Hojo N, Suzuki M, Hoshikawa T, Shimura T, Morii E, Oka Y, Hosen N, Komatsu K, Sugiyama H

   Molecular carcinogenesis　54(12) 1758-1771　2015年12月FullTxt

2. Two distinct effector memory cell populations of WT1 (Wilms' tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients.

   Nakae Y, Oka Y, Fujiki F, Morimoto S, Kamiya T, Takashima S, Nakata J, Nishida S, Nakajima H, Hosen N, Tsuboi A, Kyo T, Oji Y, Mizuguchi K, Kumanogoh A, Sugiyama H

   Cancer immunology, immunotherapy : CII　64(7) 791-804　2015年7月FullTxt

3. Transduction of a novel HLA-DRB1*04:05-restricted, WT1-specific TCR gene into human CD4+ T cells confers killing activity against human leukemia cells.

   Katsuhara A, Fujiki F, Aoyama N, Tanii S, Morimoto S, Oka Y, Tsuboi A, Nakajima H, Kondo K, Tatsumi N, Nakata J, Nakae Y, Takashima S, Nishida S, Hosen N, Sogo S, Oji Y, Sugiyama H

   Anticancer research　35(3) 1251-1261　2015年3月FullTxt

4. Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms.

   Tatsumi N, Hojo N, Sakamoto H, Inaba R, Moriguchi N, Matsuno K, Fukuda M, Matsumura A, Hayashi S, Morimoto S, Nakata J, Fujiki F, Nishida S, Nakajima H, Tsuboi A, Oka Y, Hosen N, Sugiyama H, Oji Y

   PloS one　10(6) e0130578FullTxt

5. An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells.

   Hasegawa K, Tanaka S, Fujiki F, Morimoto S, Nakajima H, Tatsumi N, Nakata J, Takashima S, Nishida S, Tsuboi A, Oka Y, Oji Y, Kumanogoh A, Sugiyama H, Hosen N

   PloS one　10(12) e0144594　2015年FullTxt